Decoding the Structural and Functional Dynamics of HER2-HER3 in Cancer through Advanced Cryo-Electron Tomography

2026-07-22

The HERSTRUCT project seeks to uncover the structural and functional mechanisms of HER2 and HER3, two proteins that are pivotal in driving cancer progression, particularly in aggressive breast and lung cancers. HER2 is often overexpressed in these types of cancers, leading to unchecked cell proliferation, while HER3 collaborates with HER2 to intensify the signaling pathways that sustain tumor growth and survival. Despite extensive research, the precise nature of the HER2-HER3 interaction in cancer cells, especially within their native membrane environment, remains elusive and closely linked to cancer resistance to therapies. Leveraging cutting-edge cryo-electron tomography (cryo-ET), the HERSTRUCT project aims to produce the first 3D structural view of the full-length HER2-HER3 complex in its natural membrane environment. This approach will provide unprecedented insights into how these two proteins function together at the molecular level. Functional assays will investigate how HER2 and HER3 trigger cancer-promoting signals, while mass spectrometry will identify additional molecules interacting with the complex, offering a complete view of their role in cancer progression and therapy resistance. In collaboration with leading research institutes, HERSTRUCT will explore how these structural insights can be applied to develop cancer therapies specifically targeting HER2-HER3 interactions. This effort not only fills a key gap in cancer research but also has the potential to lead to more personalized and effective treatments, particularly for HER2-positive cancers, where drug resistance is a challenge. The fellowship will provide me with cutting-edge expertise in cryo-ET and advanced data analysis, strengthening my skills and preparing me for a leadership role in cancer research. This project addresses a critical challenge in cancer biology and offers the potential to improve treatment outcomes for patients with HER2-driven cancers.

Germany

2026-01-01